biotech ETFs

After some huge swings in the past three years, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has been relatively quiet for the past few months, trading mostly sideways within a very narrow range. The extended consolidation period may mean the IBB’s next breakout will be a big...

Putting personal politics aside for a moment, it is not unreasonable to assume that investors who were long biotechnology stocks and exchange-traded funds into Election Day are happy with the outcome. Leading up to Election Day, Democratic nominee Hillary Clinton and her harsh rhetoric against high...

About a year after reaching all-time highs, biotechnology exchange-traded funds are rallying after starting 2016 on dismal notes. Over the past month, the three largest U.S. biotechnology ETFs are up an average of almost 15 percent. LABU And LABD Predictably, the recent biotech rally is...

In what has been a trying year for biotechnology stocks and exchange-traded funds, traders and investors are likely tired of hearing about when this group is finally going to deliver some legitimate upside. Although the popular triple-leveraged biotech ETF Direxion Daily S&P Biotech Bull 3X...

After a third-quarter swoon that saw the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) and the SPDR S&P Biotech (ETF) (NYSE: XBI), two of the largest biotech exchange-traded funds by assets, tumble 18.1 percent and 24.4 percent, respectively, traders have displayed caution regarding...

The rug was unceremoniously pulled out from under the bulls this past week as several key earnings misses and economic data surprises led to a muted decline in stocks.  The SPDR S&P 500 ETF Trust (NYSE: SPY) jostled lower for much of the week and continues to underscore the difficulty...